Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/NEU-overexpressed/amplified breast cancer: Feasibility.

Next Previous
X
Search
Trial Profile

Phase II study of dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/NEU-overexpressed/amplified breast cancer: Feasibility.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Pegfilgrastim; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Mar 2013 Additional lead trial center added as reported by ClinicalTrials.gov.
    • 27 Jul 2010 Planned end date changed from 1 Mar 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.
    • 13 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top